AXID Drug Patent Profile

When do Axid patents expire, and when can generic versions of Axid launch?

Axid is a drug marketed by Smithkline Beecham, Braintree, and Haleon Us Holdings. and is included in three NDAs.

The generic ingredient in AXID is nizatidine. Four suppliers are listed for this compound. Additional details are available on the nizatidine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Axid

A generic version of AXID was approved as nizatidine by EPIC PHARMA LLC on July 5^th, 2002.

Summary for AXID

US Patents:	0
Applicants:	3
NDAs:	3

Paragraph IV (Patent) Challenges for AXID

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AXID	Oral Solution	nizatidine	15 mg/mL	021494	1	2008-05-14

US Patents and Regulatory Information for AXID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Smithkline Beecham	AXID	nizatidine	CAPSULE;ORAL	019508-001	Apr 12, 1988		DISCN	No	No
Haleon Us Holdings	AXID AR	nizatidine	TABLET;ORAL	020555-001	May 9, 1996		OTC	Yes	Yes
Smithkline Beecham	AXID	nizatidine	CAPSULE;ORAL	019508-002	Apr 12, 1988		DISCN	No	No
Braintree	AXID	nizatidine	SOLUTION;ORAL	021494-001	May 25, 2004		DISCN	Yes	No

International Patents for AXID

See the table below for patents covering AXID around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	241439	PREPARACION DE N-TIAZOLIL-METILTIO-ALQUIL-N'-(CIANO, CARBAMOIL, NITRO P-ALQUILFENILSULFONIL O ALQUILSULFONIL) GUANIDINAS O N'-CIANO CARBAMIDO TIOATOS. (IMPROVEMENTS IN OR RELATING TO 2,4-DISUBSTITUTED THIAZOLE DERIVATIVES)
Austria	14879
Australia	542553
Australia	7594581

Last updated: February 3, 2026

What Is the Market and Investment Outlook for AXID?

The pharmaceutical drug AXID (nizatidine), primarily used for treating acid reflux and ulcers, has seen fluctuating market relevance due to patent expirations and competition from generics. Its future investment potential hinges on regulatory statuses, patent landscape, and opportunities for new indications or formulations.

What Are the Current Market Dynamics for AXID?

• AXID was originally marketed by GlaxoSmithKline (GSK). As of 2010, its exclusivity ended globally.
• The drug transitioned to a generic compound, significantly reducing its retail price and market share.
• The global market for acid reducers and H2 antagonists declined due to the rise of proton pump inhibitors (PPIs), like omeprazole and esomeprazole, which offer superior efficacy.
• As of 2022, AXID's sales are minimal, mainly driven by legacy prescriptions and niche markets.

What Are the Key Regulatory and Patent Factors Affecting AXID?

• Patent expiration occurred around 2010, leading to widespread generics.
• No recent patent filings or exclusivity extensions are in effect.
• The absence of patent protection limits investment value unless new formulations or indications are developed.
• Regulatory pathways for reformulations or new indications include preclinical and clinical trials, which require significant capital.

What Are the Opportunities for Investment or Diversification?

• Developing new formulations: Meltable tablets, sustained-release, or combination drugs to differentiate from existing generics.
• Repurposing efforts: Investigating AXID for other indications, such as gastrointestinal motility disorders or extra-gastric applications.
• Partnership with biotech firms: Licensing novel delivery systems or combination therapies.

What Is the Financial Profile of AXID?

• Due to limited sales, revenue from AXID remains negligible.
• The cost of maintaining regulatory filings for extensions or new indications is high relative to current revenue.
• Investment risk remains high unless new development pathways are pursued.

What Are the Competitive Dynamics?

Aspect	Details
Market Share	Diminished, replaced by PPIs
Price Competition	Intense, leading to margin erosion
Patent Status	Expired in all major markets
Innovation Drivers	Focus on new formulations or indications

What Are the Key R&D and Investment Considerations?

• The low profit margin for legacy AXID sales dissuades ongoing investments.
• Opportunities exist but require significant upfront investment to develop new formulations or pursue repositioning strategies.
• Regulatory hurdles for approval of reformulated or new indications may last 3-5 years.
• Market entry into new niches might be profitable if associated with patent protection or exclusivity rights.

Closing Summary

AXID's market potential is limited by patent expiration and competition from PPIs. Investment strategies should focus on innovation, including new formulations or indications. The financial outlook remains subdued unless substantial R&D investments lead to differentiated products with regulatory exclusivity.

Key Takeaways

• AXID's legacy market has declined sharply following patent loss.
• Future value depends on developing new formulations or repurposing.
• Competitive pressure from PPIs continues to suppress sales.
• High R&D costs are required for reformulation or indication expansion.
• Investment potential is cautious unless new intellectual property rights can be secured.

FAQs

1. Can AXID regain market share through new formulations?
Potentially, but success depends on regulatory approval, clinical differentiation, and market acceptance. Cost and time investments are substantial.

2. Are there patent opportunities related to AXID?
No current patents protect AXID; new patents would need to involve innovative delivery systems or new therapeutic uses.

3. Is there a commercial pipeline for AXID?
No significant pipeline exists at present; most efforts focus on other compounds or drug classes.

4. What regulatory pathways exist for reformulating AXID?
Generic reformulations typically require bioequivalence studies; novel formulations may require extensive clinical trials and regulatory approval.

5. How do AXID's prospects compare with similar H2 antagonists?
Most competing H2 antagonists are off-patient markets or available as generics, limiting growth and investment appeal for AXID.

---

References

1. MarketsandMarkets. "Gastrointestinal Drugs Market by Disease, Product, and Region." 2022.
2. U.S. Food and Drug Administration. Drug Patent and Exclusivity Data. 2022.
3. IMS Health. "Global Prescription Market Trends," 2022.